Details of the Drug

General Information of Drug (ID: DMZG5WL)

Drug Name
Emapalumab
Synonyms emapalumab; Emapalumab [INN]; Emapalumab [USAN:INN]; UNII-3S252O2Z4X; 3S252O2Z4X
Indication
Disease Entry ICD 11 Status REF
Primary haemophagocytic lymphohistiocytosis 4A01.23 Approved [1]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2/3 [2]
Affected Organisms
Humans
ATC Code
L04AA39: Emapalumab
L04AA: Selective immunosuppressants
L04A: IMMUNOSUPPRESSANTS
L04: IMMUNOSUPPRESSANTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Antibody
ADMET Property
Clearance
The clearance of drug is 0.007 L/h in healthy subjects []
Half-life
The concentration or amount of drug in body reduced by one-half in 22 days []
Metabolism
The drug is metabolized via recycling [3]
Vd
The volume of distribution (Vd) of drug is 4.2 L []
Cross-matching ID
UNII
3S252O2Z4X
DrugBank ID
DB14724
TTD ID
D0UI7K
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interferon-gamma (IFNG) TT93WF5 IFNG_HUMAN Modulator [4]
HUMAN interferon gamma (IFNG) TTR10KI IFNG_HUMAN Inhibitor [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Emapalumab (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Oliceridine DM6MDCF Moderate Altered metabolism of Emapalumab due to Oliceridine alters the formation of CYP450 enzymes. Acute pain [MG31] [6]

References

1 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (BLA) 761107.
2 ClinicalTrials.gov (NCT04324021) Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.. U.S. National Institutes of Health.
3 Li K, Xu Y: Citrate metabolism in blood transfusions and its relationship due to metabolic alkalosis and respiratory acidosis. Int J Clin Exp Med. 2015 Apr 15;8(4):6578-84. eCollection 2015.
4 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
5 Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology. 2004 Nov 10;329(1):11-7. doi: 10.1016/j.virol.2004.08.011.
6 Product Information. Cosentyx (secukinumab). Novartis Pharmaceuticals, East Hanover, NJ.